Cancer is the second leading cause of death globally, trailing only heart disease. In the
United States alone, 1.9 million new cancer cases and 609,360 deaths were recorded for …

This research work focuses on the synthesis, spectroscopic characterization, DFT studies,
and in silico molecular docking of two azo compounds;(E)-6-((4, 6-dichloro-1, 3, 5-triazin-2 …

As the most common primary tumour of the central nervous system, gliomas have a high
recurrence rate after surgical resection and are resistant to chemotherapy, particularly high …

Nanotechnology-based drug delivery platforms have shown great potential in overcoming
the limitations of conventional therapy for glioblastoma (GBM). However, permeation across …

Glioblastoma (GBM) is the most common and highly lethal type of brain tumor, with poor
survival despite advances in understanding its complexity. After current standard therapeutic …

Glioblastoma multiforme (GBM) is an aggressive brain cancer showing poor prognosis.
Currently, treatment methods of GBM are limited with adverse outcomes and low survival …

Glioblastoma (GBM) recurrences appear in most cases around the resection cavity borders
and arise from residual GBM cells that cannot be removed by surgery. Here, we propose a …

Simple Summary Introducing novel and effective treatments against glioblastoma (GBM)
remains an arduous journey as reflected in the negative outcome of most clinical trials. The …

The procollagen C-protease enhancer (PCOLCE) has been identified to influence tumor
growth and metastasis in multiple cancers. However, the relationship between PCOLCE …

Gemcitabine (GEM) repurposing for glioblastoma (GBM) therapy has been investigated as a
fast-track approach to circumvent the drug resistance mediated by the O 6-alkylguanine …